GoodRx, a prominent platform for medication savings in the U.
S., has announced that Repatha® (evolocumab), a therapy designed to lower cholesterol, is now accessible at a significantly reduced cash price. Patients can acquire Repatha for $239 through GoodRx at over 70,000 pharmacies across the nation, representing a savings of nearly 60% off the standard retail pharmacy list price.
Laura Jensen, Chief Commercial Officer and President of Pharma Solutions at GoodRx, stated, “In a healthcare system where affordability too often dictates access, GoodRx remains focused on delivering meaningful savings to patients at scale. GoodRx is serving as the digital storefront to make Repatha more accessible for patients, leveraging our extensive retail pharmacy network to ensure it’s available where they already fill their prescriptions. This combination of meaningful savings and broad distribution helps break down barriers so patients can start and stay on the therapies that matter most for their health.”
By making Repatha available at a lower cash price than previously offered in retail settings, GoodRx and Amgen are collaborating to help patients navigate traditional insurance obstacles. These often include restrictive formularies and high deductibles, which can delay or prevent necessary treatment. GoodRx is developing direct-to-consumer solutions that offer pharmaceutical brands a reliable and scalable channel to provide savings directly to patients.
GoodRx serves nearly 30 million consumers and over one million healthcare professionals annually. The platform is strategically positioned within the healthcare ecosystem, connecting consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to streamline medication savings. Since its inception in 2011, GoodRx has facilitated over $85 billion in medication cost savings for Americans.
